Combination immunotherapy: Where do we go from here?

Abigail E. Overacre, Sema Kurtulus, Mario Sznol, Drew M. Pardoll, Ana Anderson, Dario A.A. Vignali

Research output: Contribution to journalArticle


The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against "immunologically inert" tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014.

Original languageEnglish (US)
Article number38
JournalJournal for immunotherapy of cancer
Issue number1
StatePublished - Aug 18 2015


  • Cancer
  • Exhaustion
  • Immunology
  • Immunotherapy
  • T cells
  • Therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination immunotherapy: Where do we go from here?'. Together they form a unique fingerprint.

  • Cite this

    Overacre, A. E., Kurtulus, S., Sznol, M., Pardoll, D. M., Anderson, A., & Vignali, D. A. A. (2015). Combination immunotherapy: Where do we go from here? Journal for immunotherapy of cancer, 3(1), [38].